All Therapeutics articles – Page 4
-
NewsIpsen selects Pierrick Lefranc as new EVP Technical Operations
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.
-
NewsUK ‘gaining pace’ with early-stage trials for advanced therapies
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
-
NewsWuXi Biologics partners with HanchorBio on next-gen immunotherapies
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
-
NewsAdvanced manufacturing research supports automated production of critical API
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
-
NewsHoth Therapeutics’ topical therapy shines in cancer toxicity trial
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
-
NewsEurope marks key milestone in adopting Critical Medicines Act
EU Parliament agrees clear priorities for future negotiations on the act, including investing in pharma manufacturing capacity.
-
NewsGSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
-
News
Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
-
NewsJohnson & Johnson’s Caplyta demonstrates phase III promise for depression
Combination therapy comprising of an antidepressant and small molecule drug significantly boosted remission rates in adults with major depressive disorder.
-
NewsTeva’s migraine biologic Ajovy marks phase III progress for paediatric patients
The monoclonal antibody could provide a new preventative treatment option for episodic migraines, new late-stage data suggests.
-
NewsPolymer capsule drug delivery innovation demonstrates sustainability promise
Synthesis of the naturally-derived capsules provide a sustainable alternative to traditional, microplastic-contributing drug delivery options.
-
NewsEMA and FDA issue joint AI guidance for medicine development
The regulators’ 10 principles aim to support pharma companies with evidence generation and monitoring for new medicines.
-
News
AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
-
NewsEuropean Pharmacopoeia publishes new data quality framework
New general chapter on quality of data 5.38 supports stakeholders with digitalisation during pharmaceutical quality decision-making.
-
NewsSentynl secures US-first approval for rare Menkes disease
The US biopharma company can now offer a new treatment option for eligible paediatric patients with the genetic disease.
-
NewsSanofi wins EU approval for its type 1 diabetes biologic Teizeild
The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe.
-
NewsNovartis to site its fourth US radioligand manufacturing facility in Florida
The new Winter Park plant advances the pharma company’s $23 billion commitment to enhance its US radioligand medicine manufacturing capabilities.
-
NewsEndotoxins research supports recombinant reagent use for pharma QC
Replacing LAL reagents with animal-free alternatives addresses industry commitments to improve QC practices’ ethics and sustainability.
-
NewsAstraZeneca hires Rick Suarez to lead its biopharma efforts in the US
His appointment comes as the pharma company AstraZeneca seeks to hit $80 billion revenue target by 2030.
-
NewsLilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal
The deal brings it access to oral therapies targeting inflammatory-mediated conditions, including cardiometabolic, neurodegenerative and autoimmune diseases.